The development of new treatments for any disease relies on the collaborative efforts of many different stakeholders, such as scientists, clinicians, patient advocacy groups, regulators, and pharmaceutical and biotech companies. During scientific conferences that happen throughout the year, stakeholders cobble together opportunities to discuss the current state of treatments and strategize ways to bring emerging lifesaving treatments to patients. Each year, there is one key conference dedicated to bringing these stakeholders together with the sole goal of discussing the development of

Lung squamous cell carcinoma (LSCC), also called squamous cell lung cancer, is one of the major subtypes of non-small cell lung cancer (NSCLC). Fifty years ago, LSCC was the most common lung cancer diagnosis. LSCC was considered the classic smoker’s lung cancer, as most patients with LSCC had a history of smoking cigarettes. Today, the incidence of LSCC depends on where you live. In areas with decreasing smoking rates, we’ve also seen a reduction in the number of LSCC diagnoses. Overall, while lung adenocarcinoma is now the most common type of NSCLC in the US, approximately 15-30% of lung

Communication is critical to a positive doctor-patient relationship. Knowing the right questions to ask helps ensure you leave your appointments with the information and answers you need. Being prepared may also lessen anxiety and help provide a sense of control. Meeting with your oncologist, especially when first diagnosed or deciding on a treatment plan, are times when being prepared with questions is necessary. LUNGevity has downloadable lists of questions that you can bring to appointments to make gathering information and taking notes easier. Below are sample questions for different

Brain metastases are known to occur in approximately 25% of patients diagnosed with lung cancer. This webinar dives into the details of brain metastasis in lung cancer to explore their signs and symptoms. It also includes a discussion of treatment considerations. Through this webinar, you will learn to: Understand how brain metastasis occurs Keep an eye out for signs & symptoms of brain mets Understand treatment options and management techniques This webinar was created in partnership with LUNGevity Foundation and American Brain Tumor Association with support from Novocure. Hosts: Upal Basu

Pulmonary rehab expert Debbie Koehl, MS, RRT-NPS, AE-C, FAARC, speaks to LUNGevity's Survivorship Navigator, Kristi Griffith, to explain what pulmonary rehabilitation is, explore the benefits of pulmonary rehabilitation, and gain key insights about how to obtain pulmonary rehabilitation for yourself or a loved one. The discussion is followed by an informal Q&A with other lung cancer survivors. This recording was made during one of LUNGevity Foundation's Virtual Meetups -- a free resource for the lung cancer community. See the full schedule of Virtual Meetups at lungevity.org/meetups.

In this video, nurse practitioner Lauren Welch, MSN, NP-C, AOCNP, from the Sarah Cannon Research Institute at Tennessee Oncology offers a quick review of pneumonitis - a common side effect of some lung cancer treatments. Survivors and caregivers can learn: What is pneumonitis? What causes it? How is it treated? What symptoms should we look out for?

Lung cancer survivor Jill Feldman joins radiation therapy experts Drs. Drew Moghanaki and Kristin Higgins to provide an overview of radiation therapy – including discussions of when this treatment is recommended, how the treatment is administered, and which side effects are most common.

Drs. Upal Basu Roy, Amy Moore, and Dhru Deb discuss their recent publication in which they presented an analysis of the lung cancer drug pipeline. They talk about what it means for patients, new drugs under development for NSCLC and SCLC, and some of the ongoing challenges and opportunities this rapid growth means for the lung cancer community.

Lung cancer continues to be the number-one cause of cancer deaths in the United States. In the past decade, we have seen great improvements in the treatment of metastatic lung cancer with targeted therapies and immunotherapy. “When targeted therapies aren’t an option, the current standard of care for patients is immunotherapy alone or in combination with chemotherapy. But many patients don’t respond to these treatments the way we’d like them to,” said Sean Pitroda, MD, assistant professor of Radiation and Cellular Oncology at the University of Chicago. “Our standard treatments do improve

Historically, surgery has been the most effective treatment for patients with early-stage non-small cell lung cancer (NSCLC). While technological improvements, such as the development of minimally invasive techniques (such as video-assisted thoracoscopic surgery or VATS), have made surgeries safer for patients, the ability to cure early-stage NSCLC patients hasn’t improved significantly in recent decades. Even after successful surgeries that completely remove the visible tumor, about half of these patients will face a recurrence with their cancer coming back within five years. Researchers have